Difficulty: Medium
Average Score: 75%
Practice
Neuromuscular blockade by both succinylcholine and mivacurium may be prolonged in patients with:
Correct answer
B
Rationale
The correct answer is B) An abnormal variant of plasma cholinesterase.
In the context of neuromuscular blockade caused by succinylcholine and mivacurium, the presence of an abnormal variant of plasma cholinesterase can lead to prolonged effects of these drugs. Plasma cholinesterase is an enzyme responsible for metabolizing succinylcholine and mivacurium. When an abnormal variant of this enzyme is present, it results in a decreased ability to break down these neuromuscular blocking agents, leading to prolonged paralysis.
Option A) Renal failure is incorrect because renal failure typically does not directly impact the metabolism of succinylcholine and mivacurium. These drugs are primarily metabolized by plasma cholinesterase, which is not directly affected by renal function.
Option C) Hepatic disease is also incorrect in this context because the metabolism of succinylcholine and mivacurium is primarily dependent on plasma cholinesterase, which is not primarily produced or affected by the liver.
Option D) Both B and C is incorrect because hepatic disease alone does not significantly impact the metabolism of succinylcholine and mivacurium, as mentioned earlier. The key factor in the prolonged effects of these drugs is the presence of an abnormal variant of plasma cholinesterase.
Educationally, understanding the factors that can influence the pharmacokinetics of drugs is crucial for healthcare providers, especially those involved in anesthesia and critical care. Knowledge of how variations in enzyme function can affect drug metabolism helps in optimizing patient care and avoiding potential complications related to drug effects. Identifying patients with abnormal variants of plasma cholinesterase can guide anesthetic management decisions and prevent adverse events related to prolonged neuromuscular blockade.
In the context of neuromuscular blockade caused by succinylcholine and mivacurium, the presence of an abnormal variant of plasma cholinesterase can lead to prolonged effects of these drugs. Plasma cholinesterase is an enzyme responsible for metabolizing succinylcholine and mivacurium. When an abnormal variant of this enzyme is present, it results in a decreased ability to break down these neuromuscular blocking agents, leading to prolonged paralysis.
Option A) Renal failure is incorrect because renal failure typically does not directly impact the metabolism of succinylcholine and mivacurium. These drugs are primarily metabolized by plasma cholinesterase, which is not directly affected by renal function.
Option C) Hepatic disease is also incorrect in this context because the metabolism of succinylcholine and mivacurium is primarily dependent on plasma cholinesterase, which is not primarily produced or affected by the liver.
Option D) Both B and C is incorrect because hepatic disease alone does not significantly impact the metabolism of succinylcholine and mivacurium, as mentioned earlier. The key factor in the prolonged effects of these drugs is the presence of an abnormal variant of plasma cholinesterase.
Educationally, understanding the factors that can influence the pharmacokinetics of drugs is crucial for healthcare providers, especially those involved in anesthesia and critical care. Knowledge of how variations in enzyme function can affect drug metabolism helps in optimizing patient care and avoiding potential complications related to drug effects. Identifying patients with abnormal variants of plasma cholinesterase can guide anesthetic management decisions and prevent adverse events related to prolonged neuromuscular blockade.